QR code

Real-World Treatment and Outcomes in ALK-Rearranged NSCLC: Results From a Large U.S.-Based Database

Introduction: ALK–rearranged advanced NSCLC (aNSCLC) represents 4% of all NSCLCs, and multiple ALK-targeted therapies (ALK-inhibitors) are now available for use. Little is known about changes in treatment patterns, or how prognostic factors and sequence of therapy may impact overall survival in the...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Grace Chazan, M.B.B.S., BSc, FRACP, Fanny Franchini, BSc, MSc, DPhil, Roma Shah, MPH, Marliese Alexander, BPharm (Hons), MPH, PhD, Ani John, PhD, Maarten IJzerman, BSc, MSc, PhD, Benjamin Solomon, M.B.B.S., PhD, FRACP
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Elsevier 2024-08-01
Reeks:JTO Clinical and Research Reports
Onderwerpen:
ALK+ lung cancer
Prognostic factors
Treatment sequence
Real-world
Online toegang:http://www.sciencedirect.com/science/article/pii/S2666364324000328
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items